Pulse nav.journalClub Trends Entdecken Fragen Forschende

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Datenschutz

Start Entdecken nav.journalClub Trends

⌘+K

Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk | Synapse

November 18, 2013Open Access

Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk

Key Points

Key points are not available for this paper at this time.

Abstract

http://www.clinicaltrials.gov. Unique identifier: NCT00239681.

Read Full Paperexternally

Like

Bookmark

Share

View Full Paper

Like

Bookmark

Share

View Full Paper

Cite This Study

Khera et al. (Mon,) studied this question.

synapsesocial.com/papers/69d8c8eb183921ebcaae3abe https://doi.org/https://doi.org/10.1161/circulationaha.113.004406

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Serum Lipoprotein(a) Level and its Clinical Significance in Patients with Systemic Lupus Erythematosus2002 · 39 citations
2Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia2010 · 179 citations
3Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease2010 · 754 citations
4Effects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a)1995 · 291 citations
5Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein2008 · 6,625 citations